Executives

Prior to founding Curavit, Joel Morse co-founded and served as CEO of C3i, a $100 million, global, tech-enabled services company that served the world’s leading pharmaceutical, contract research, and clinical technology companies. Joel sold C3i to Merck (NYSE: MRK) in 2014, where he merged it with Telerx, another wholly-owned subsidiary of Merck.  At Merck, Joel served as president of the combined $200 million subsidiary, and subsequently sold the company to, and integrated it with, HCL Technologies (NSE:HCLTECH).   Joel has an MBA from Columbia University and BSME from Tufts University.

 Dave is a proven entrepreneur, operator, and board director with successful, strategic exits to public companies. Co-founder with Joel at C3i, Dave developed its sales, marketing, product development, and alliance strategies. Currently, Dave is an investor and serves as a board member and adviser to several start-ups and growth-stage companies in healthcare and technology. 

Dr. Diamond is a Board Certified, Boston-based Otolaryngologist/Head and Neck Surgeon who was affiliated with Harvard Medical School (HMS) and Massachusetts Eye and Ear Infirmary (MEEI) for over 30 years. She joined Curavit in 2019 as a co-founder and Chief Medical Officer, and provides medical and scientific expertise and oversight to the design and execution of Curavit's decentralized clinical trials. Dr. Diamond received her medical degree from the University of Rochester School of Medicine and completed her Otolaryngology/Head and Neck Surgery residency at HMS/MEEI.

  Todd is a full-stack software engineer with a deep background in EHR system integration, Machine Learning, and large data analytics. Projects include META and IDseq for the Chan-Zuckerberg Initiative & launching the Kela Health program at Duke Medical.